VINDESINE (desacetylvinblastine amide) is a semisynthetic derivative of the Vinca alkaloid group that may be prepared from vinblastine or desacetylvinblastine (Barnett et al., 1978) . As a result of its activity against a range of experimental tumours, the alkaloid has been introduced into the clinic, where useful therapeutic results have been obtained; its clinical toxicity includes both neurological impairment of the type seen during treatment with vincristine, and marrow depression like that produced by vinblastine (Dyke & Nelson, 1977) . The pharmacokinetic pattern of vindesine in humans closely resembles that of vinblastine, and both are cleared more rapidly than vincristine (Owellen et al., 1977) . Vindesine interacts with tubulin and inhibits its polymerization (Owellen et al., 1976) , but no studies have yet been made to determine whether the drug interferes with the other biochemical pathways known to be affected by vinblastine, vincristine and vinleurosine (Creasey, 1979) . The present study demonstrates that vindesine does indeed have the capacity to inhibit major biochemical pathways.
Sarcoma 180 (S180) cells in the ascites form were maintained in adult Swiss mice (CD-1) and harvested [4] [5] [6] was studied by incubating cells with the tracer in a final volume of 3 ml serumbuffer in Warburg flasks. Reactions were stopped by tipping in perchloric acid (0-3 ml 1M) from the side arm, and 14CO2 released during the incubation was collected on filter paper moistened with 0-1 ml of IM NaOH in the centre well. These procedures have been described in detail in earlier publications (Creasey, 1969 (Creasey, , 1976 Creasey & Markiw, 1965) . The collected data in the figure indicate that at the higher concentrations of vindesine all the parameters examined were inhibited. suggest that, whilst a direct drug may occur on DNA synt levels, much of the inhibition other parameters at higher co may be nonspecific, and ascri effect on glucose oxidation. I cetrain respiratory processes has been reported for other Vinca alkaloids (Hunter, 1963; Obrecht & Fusenig, 1966) , but in the S180 tumour we found that neither vincristine nor vinblastine (at concentrations below 0-3 ,uM) inhibited the oxidation of glucose to CO2. Comparison at the 2 highest drug levels indicated that vindesine generally gave greater inhibition of 3 selected biochemical parameters than did vincristine or vinblastine, though the latter produced a greater effect on RNA synthesis (Table) . The rate of agglutination of tumour cells by concanavalin A (25 ,ug/ml) was measured spectrophotometrically (Murphree et at., 1976 (Burton, 1956 (Creasey, 1975; Graff et al., 1967; Krowke et al., 1970) . Incorporation of precursors into protein and RNA was not affected significantly, in contrast to treatment with vincristine which inhibited protein and RNA synthesis by 58 and 3400 respectively at 24 h; 6h values were almost identical. Vinblastine exerted smaller, less reproducible effects than vincristine. The latter drug is known to have significantly longer half-lives in the body than either vinblastine or vindesine, and thus is likely to have greater biochemical effects.
Levels of vindesine were determined by radioimmunoassay (Root et al., 1975) in ascitic fluid (separated from cells) over a period between 10 min and 6 h after drug injection. Mean values (3 mice per point) fell from an initial maximum of 0-32 MM to 0 025 at 1 h and 0-001 at 6 h. Only during the first hour, therefore, were vindesine levels in the range required to inhibit biochemical pathways in vitro, with inhibitory concentrations persisting longest in the case of incorporation of [3H]dT into DNA. Presumably there is prolonged persistence of drug within the tumour cells, enabling inhibition to be maintained for 24 h.
Thus, vindesine also exerts the biochemical interventions previously described for the other Vinca alkaloids, and indeed, may be a more effective inhibitor under the in vitro conditions used here. DNA synthesis is most sensitive to lower vindesine concentrations, and is the only process affected significantly both in vivo and in vitro. Suppression of the oxidation of glucose may be a factor in the relatively nonspecific inhibition seen at higher dose levels in vitro. Despite these apparently more potent actions in vitro, vindesine is less effective as a metabolic inhibitor than the other 2 alkaloids in vivo, a finding compatible both with the smaller antitumour effect on S180 seen during development of this drug (Eli Lilly & Co., 1975) and with a comparison made in our own laboratory, where vindesine produced a maximum increase in lifespan of 106% compared with 186% for vinblastine at 0-25 mg/kg/day for 6 days. Pharmacokinetic differences may be responsible for this difference. Further studies of the relation of the effect on glucose metabolism to other aspects of vindesine action are warranted, since the sensitivity of this process appears to be unique to this alkaloid among the V;inca group. These will be undertaken in the P388 tumour, which behaves similarly to 8180, because of recent problems with carrying the latter neoplasm in mice.
